AI Drug Discovery

Business

Twist Bioscience Powers Ahead: Q1 2026 Revenue Jumps 17%, Fueled by AI-Driven Discovery Boom

Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.

Feb 2, 2026

Business

Corcept Therapeutics Stock Plummets as FDA Reveals It Warned Company Against Drug Submission

Shares of Corcept Therapeutics plunged 16% after a corrected FDA letter disclosed the agency had repeatedly cautioned the company against filing its application for a Cushing's syndrome drug, which was later rejected over efficacy and safety concerns.

Jan 30, 2026

Business

Alumis Soars as Psoriasis Drug Hits All Phase 3 Goals, Drawing Bullish Analyst Praise

Clinical-stage biopharma Alumis Inc. (ALMS) is gaining significant Wall Street attention after its lead drug candidate, envudeucitinib, successfully met all endpoints in key Phase 3 trials for plaque psoriasis, prompting multiple analyst upgrades and optimistic price targets.

Jan 30, 2026

Business

Wall Street Bets on Smooth Sailing for Netflix-Warner Bros. Discovery Merger

As speculation intensifies over a potential acquisition of Warner Bros. Discovery by Netflix, short sellers are rapidly retreating from the stock, signaling market confidence in both the deal's completion and regulatory approval.

Jan 30, 2026

Business

Regeneron Aims to Redefine Obesity Treatment with Dual-Action Drug Targeting Weight and Cholesterol

Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.

Jan 30, 2026

Sanofi's Long-Delayed Rare Disease Drug Shows Promise for Neurological Gaucher, Falters in Fabry

After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.

Feb 2, 2026

US

Gruesome Discovery: Dismembered Woman Found in Brooklyn Public Housing Basement

NYCHA workers in Williamsburg made a horrific discovery on Sunday morning, finding a woman's dismembered remains inside a heavy bag in a building basement, sending shockwaves through the community.

Feb 2, 2026

Business

Analysts Bullish on Ardelyx Ahead of Q4 Earnings, Citing Blockbuster Potential for Key Drug

Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.

Feb 2, 2026

Business

Janux Therapeutics Downgraded as Key Drug Data Gaps Raise Platform Concerns

Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.

Feb 2, 2026

Business

Eli Lilly Bets Big on Pennsylvania with $3.5 Billion Plant for Next-Gen Weight Loss Drugs

The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.

Feb 2, 2026

Business

Terns Pharma Secures Global Rights for Key Drug, Fueling Expansion Ambitions Beyond China

Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.

Feb 2, 2026

Sanofi's Genetic Disorder Drug Shows Promise in Gaucher Trial, Stumbles in Fabry Study

Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.

Feb 2, 2026

Business

Day One Biopharmaceuticals: Surging Momentum Raises Valuation Questions Amid High-Stakes Pipeline

Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.

Jan 31, 2026

Business

AstraZeneca's Valuation Puzzle: Strong Pipeline and Steady Gains Mask Undervalued Opportunity?

Despite a robust drug pipeline and steady long-term gains, AstraZeneca's recent share price stagnation has investors questioning its true worth. A deep dive into valuation models suggests the pharmaceutical giant may be trading at a significant discount to its intrinsic value, even as its P/E ratio appears elevated compared to peers.

Jan 31, 2026

Business

Century Therapeutics Gains Analyst Confidence with Extended Cash Runway and Key IND Submission on Horizon

Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.

Jan 30, 2026

Business

Netflix's $82.7B Bid for Warner Bros. Discovery: A High-Stakes Gamble That Could Reshape Streaming

Netflix's unprecedented all-cash offer to acquire Warner Bros. Discovery has sent shockwaves through the media industry, setting the stage for a fierce regulatory battle and raising fundamental questions about the streaming giant's financial strategy and market dominance.

Jan 30, 2026

Business

LifeSci Capital Boosts Price Target on Olema Pharmaceuticals, Citing Promising Breast Cancer Drug Pipeline

LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.

Jan 30, 2026

Business

Genmab Shares Face Target Cut After EPKINLY Trial Misses Survival Goal, But Analysts Keep Faith

H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.

Jan 30, 2026

Business

Fractyl Health Charts Path for Revita as Potential Solution to Post-GLP-1 Weight Regain

Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.

Jan 30, 2026

Business

Vera Therapeutics Sees Major Price Target Hikes as Analysts Bet Big on Its Kidney Disease Drug

Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.

Jan 30, 2026